<SEC-DOCUMENT>0001193125-22-305327.txt : 20221215
<SEC-HEADER>0001193125-22-305327.hdr.sgml : 20221215
<ACCEPTANCE-DATETIME>20221215074508
ACCESSION NUMBER:		0001193125-22-305327
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221215
FILED AS OF DATE:		20221215
DATE AS OF CHANGE:		20221215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		221463650

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d421473d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2022, Kazia Therapeutics Limited (the &#147;Company&#148;) issued an ASX announcement titled, &#147;Kazia
Launches Preclinical Collaboration with QIMR Berghofer Medical Research Institute and Announces Patent Filing.&#148; A copy of this release is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quotes of Professor
Sudha Rao, and Dr.&nbsp;James Garner contained in Exhibit 99.1, into the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d421473dex991.htm">ASX Announcement of Kazia Therapeutics Limited dated December&nbsp;15, 2022 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 15&nbsp;December 2022</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d421473dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g421473dsp3.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX ANNOUNCEMENT </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15&nbsp;December 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA LAUNCHES
PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 15</B><B></B><B>&nbsp;December
2022</B> &#150; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with QIMR Berghofer Medical Research Institute, one of Australia&#146;s foremost cancer
research centres, to explore novel uses of paxalisib in solid tumours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research project is led by Professor Sudha Rao, a leading expert in
transcriptional biology, particularly as it applies to the function of the immune system in cancer. Professor Rao&#146;s laboratory works closely with pharmaceutical companies and with clinicians to explore innovative approaches to cancer treatment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration is ongoing and will build on initial research that has already led to the filing of a patent, including the use of paxalisib as an
immune modulator in the treatment of diseases such as breast cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paxalisib is a member of a class of drugs known as PI3K inhibitors. The direct anti-cancer effects of PI3K
inhibitors are well demonstrated, and five therapies have been approved by the US FDA to date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Professor Rao&#146;s research identifies an entirely separate effect of PI3K inhibition: as a modulator of the
immune microenvironment within and around the tumour. Administration of PI3K inhibitors such as paxalisib, at doses and frequencies different to those conventionally used, appears to activate the immune system in the tumour, making it more
susceptive to immunotherapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The research opens up an important opportunity for paxalisib in combination with drugs such as Keytruda<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab, Merck) and Opdivo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (nivolumab, Bristol Myers Squibb) for the treatment of diseases such as breast cancer and lung cancer.
If proven effective in clinical trials, such combinations may have the potential to improve outcomes for patients. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is anticipated that the results of the research will be published in 1H CY2023, and discussions are ongoing
regarding potential translation to clinical trials in CY2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These are very promising data,&#148; commented Professor Rao,
Principal Investigator on the project. &#147;In treatment-resistant <FONT STYLE="white-space:nowrap">pre-clinical</FONT> models of breast cancer, paxalisib has shown encouraging results in inhibiting both the primary tumour burden and metastasis by
reinvigorating the immune system within the tumour microenvironment. We look forward to continuing our research, and hopefully seeing this work lead to a clinical trial in due course.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Professor Rao&#146;s team are working at the leading edge of cancer research, and we are enormously grateful for their work on paxalisib,&#148; said Dr
James Garner, CEO of Kazia. &#147;An important part of our recent strategy for the drug has been to expand its field of opportunity outside of cancers of the brain. This work, which has primarily focused on breast cancer, but which has applicability
to other solid tumours, builds on some promising data we previously shared which demonstrated the potential of paxalisib in melanoma. We look forward to working with the QIMR Berghofer team to take this research to the next stage.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For More Information, Please Contact:- </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jane Lowe </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jane.lowe@irdepartment.com.au </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone: +61 411 117 774 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM
AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in
August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, and Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801. Such statements are based on Kazia&#146;s
expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking
statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and the related to the impact of global economic conditions. These and other risks and
uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this
announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g421473dsp3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g421473dsp3.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * %1'D<)
M&I=SP%49)H2OL)M)78Z6"6"3RYHGC?\ NNI!IM-:,(R4E=,=-:W%N%,\$D0;
M[N]2,_G0XM;H49QE\+N14B@H * "@ H * "@ H * "@ H * "@ H * "@ H
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M#AAZTU)/03BT8M42% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % &WX:TNUU.[E6Y)*QKD(#C=6U&"F]3CQ=:5**<2VWV/PUXG! 9X#'TZF//
M_P"K\C5^[2J&:Y\50\_S(]9UVUN]6LKB"(O';-DEA@OR#C]*52JI2370=##S
MA3E&3W)O$.OV6I6$=O;ABQ<,69<;:=6K&<;(G"X:=*;E(FU7PYI]GHC7$3L)
M8U!#ELA_PJJE&,871%'%5)U>5['(UR'J!0 4 % !0 4 % !0 >PH * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M61X)72<X4 >E?!_P]]NUF;69TS#9#;'D<&0C^@_F*RJ2LK&M-:W,+XC>'O\
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 /,TK6Z0%R8D8NJ=@2 "?\
MQT?E0 R@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M3G^R!IWRJ^>?E7H!T[#%:*<4K&3A)NYYE+$T,SQ/PR,5/U%;&19TK_D,6/\
MUW3_ -"%)[#6Y[G\7?\ D17_ .OB/^M<]/XC>I\)X#72<YWOPH\/?VKXF_M"
M9,VVG@2<C@R'[H_#D_@*RJ.RL:4U=W/6O$,OA34!_9VNWMD?)8.89;G85.."
M0".Q_6L8\RU1L^5Z,LZ,WA^736TK2+BUGM(D*M#%,) JMG@\DX/-#O>[&K;(
M^=_%.AOX=\1WFFMG9&^8F/\ $AY4_E^M=,7=7.:2L[&/5$A0 4 % !0 4 %
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MN*L<[J%]+J6I7-].%$MQ*TKA1@ DY.*I*RL2W=W.PL/BQXBL-/AL]MI.L2;
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M:7,ZF2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVMQ4TUC:K/+<0P"0$QK(3EP/H./QH4-+MB=5*7*DV(=/9+!+MYHD#@E$.=S
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 *CO&X>-V1AT*G!%"=MA-)JS+FFZG-IM^+M1YC8(8,?O ^]7";A*
MYE5HJK#D+6I>()]0O;>X6-8OLYW(N<\Y!Y_(54ZKDT^QG2PT:<7&][DFK>))
MM4LUMC L2Y!8@YSC^5.I6<U8FAA(T9<U[F,9'9 A=B@Z*3P*QN==DG<;0,*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
K * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
